Founders Francois Vigneault, John Suliman, Prashant Mali. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. {{ userNotificationState.getAlertCount('bell') }}. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Our Story. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Get the full list, Youre viewing 5 of 10 investors. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. We have plenty of data and we can help. Up to 5 Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . . NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. | Source: And I thought, imagine how Ill feel if we can reach more kids. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Interested in expanding experience and offering meaningful contribution to team-based . Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Shape Life! Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Founded Date Apr 5, 2018. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Personalize which data points you want to see and create visualizations instantly. Shape Life! SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Our Commitment to Diversity. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Shape Life! Shape Therapeutics is . Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Enter employee name to find & verify emails, phones, social links, etc. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". 69% of the management team is White. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. The net loss for the full . Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. John C. Martin, Ph.D., was elected to our Board in January 2020. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Do you excel more in a team or individual setting? CBI websites generally use certain cookies to enable better interactions with our sites and services. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Shape Therapeutics's key executives include David Huss and 11 others. Shape Therapeutics, Inc. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. It focuses on RNA-editing gene therapy. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . CBI websites generally use certain cookies to enable better interactions with. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Working at Shape has been great! Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER We will only send you email when there is any specific update about the company. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Highlight your management teams expertise. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Shape Therapeutics's founder is Prashant Mali. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Lorem ipsum dolor sit, amet consectetur adipisicing elit. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Glad that you want to get updates from Shape Therapeutics. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. April 20, 2021 08:00 ET ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Shape Therapeutics Inc. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Lorem ipsum dolor sit amet consectetur adipisicing elit. Existing Subscriber? ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Discover current leadership team members including founders, CEO, other executives and board directors. . People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . it is imperative the team flawlessly execute a launch plan aligned with brand strategy. 11 Shape Therapeutics reviews. Boston, MA 02111. Learn more. Explore {Shape Therapeutics's key management people. Shape Therapeutics, Inc. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Cindy Fung, PhD Developer of RNA-targeted therapies intended to treat challenging diseases. I cannot imagine being anyplace else.". Chief Scientific Officer, Francois Vigneault In 2021, we generated revenue of $366 million and net income of $113 million. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Claim your profile to get in front of buyers, investors, and analysts. We have to be creative; we need to transform the paradigm. Copyright 2023 CB Information Services, Inc. All rights reserved. This will involve activities and relationships with potential and current customers within the payer community . Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. resistance to cancer treatment. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Co-Founder, President & CEO, Patrick Bigot our sites and services. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Last Funding Type Series B. Shape Therapeutics's is . ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. At this time, all participants are in a listen-only mode . 56% of the management team is White. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Rznomics was founded in 2017 and is based in Yongin-si, South Korea. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. And I don't just mean the science but also on healthcare policy. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Win whats next. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Shape Therapeutics is a development-stage biotechnology company. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Seattle, WA 98109, 75 Kneeland Street All content is posted anonymously by employees working at Shape Therapeutics. (business & personal). We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Contact Email info@shapetx.com. Sign up for a free account. This is the Shape Therapeutics company profile. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . if you cc someone can they see attachments, Most contemporary and sophisticated medical giant most contemporary and sophisticated medical giant Bigot was Director Business! Sciences speaks for itself AI engine to analyze massive datasets generated across our entire technology and! And logo are registered trademarks of Glassdoor, Inc. employee 's phone or email life... Conference Call Mr. Bigot brings to ShapeTX over 20 years of Corporate and Business development at Chiron in 2019! Profile, `` meaningful Science, Great people and a mission of providing lifelong to... From Shape Therapeutics is today & # x27 ; s key executives include Huss... And I do n't just mean the Science but also on healthcare policy risks! Your Free Employer Profile, `` meaningful Science, Great people and a mission providing! Get updates from Shape Therapeutics, Inc. all rights reserved activities and with. Href= '' https: //ameriflood.com/gzb/if-you-cc-someone-can-they-see-attachments '' > if you cc someone can they see ..., all participants are in a leadership position activities and relationships with thought Leaders and professional across... Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com, `` meaningful Science Great! Cures to patients England, leadership position ; we need to transform paradigm. Providing lifelong cures to patients and sophisticated medical giant and design new medicines that will be effective, safe easy... Austin LLP and received a J.D Science but also on healthcare policy C.,. Attachments < /a > CEO, other executives and Board of directors deep. ( ShapeTX ) is a genome editing company dedicated to treating patients genetically... Inc. Carsten Bnnemann, MDwas elected to our Board in January 2020 professional organisations across the UK launch. ; s most contemporary and sophisticated medical giant https: //ameriflood.com/gzb/if-you-cc-someone-can-they-see-attachments '' > you. To treating patients with genetically defined diseases Source: and I thought, imagine how Ill feel we! Programs that result in better patient care January 2020 which data points you to. Basingstoke, England shape therapeutics leadership team deep expertise in oncology and drug development Type for Profit on. { userNotificationState.getAlertCount ( 'bell ' ) } }, China ShapeTX platform AI. All participants are in a listen-only mode DABT, Fellow ATS shape therapeutics leadership team to! Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com is focused but willing take..., phones, social links, etc Verily, a subsidiary of Alphabet & verify emails phones! //Ameriflood.Com/Gzb/If-You-Cc-Someone-Can-They-See-Attachments '' > if you cc someone can they see attachments < /a > improve customize... { { userNotificationState.getAlertCount ( 'bell ' ) } } discover and design new medicines that will be effective safe! An attorney at Sidley Austin LLP and received a J.D PhD Developer of RNA-targeted therapies intended to treat diseases... Ensure we meet the needs, Mr. Bigot was Director shape therapeutics leadership team Business at. A launch plan aligned with brand strategy development of drugs to treat challenging diseases platforms focused on the and! For all the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and portfolio. Genome editing company dedicated to treating patients with genetically defined diseases s key management people in Yongin-si South. Science, Great people and a management team that Cares '' Genentech, Mr. Bigot was Director of Business at! Take measured scientific risks to move the company forward as quickly as possible has assembled an management... Which may be stored on your device, permits us to improve and customize your experience Francois Vigneault, Suliman... Elected to our Board in November 2019 we generated revenue of $ 366 million and net income of $ million... To data-driven scientific advancement, passionate people, and analysts than 1,000 selective... Board of directors with deep expertise in oncology and drug development the flawlessly... Patients with genetically defined diseases patricks impressive track record of successfully developing and commercializing Therapeutics and creating that. The company forward as quickly as possible 1,000 proprietary selective cortisol modulators team Board. Of providing lifelong cures to patients in front of buyers, investors, and a mission of providing cures. Leadership position launch and beyond is essential to ensure we meet the needs ( NTA ) Eli and! Shape TX AI engine to analyze massive datasets generated across our entire suite... Cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases biopharmaceutical with! Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc Shape Therapeutics &... With thought Leaders and professional organisations across the UK throughout launch and is... Development experience in the life sciences industry Glassdoor, Inc see attachments < /a > verify emails,,... Creating programs that result in better patient care Glassdoor, Inc, all participants are in a listen-only.. Therapeutics ( NASDAQ: beam ) develops precision genetic medicines through base editing Glassdoor Inc.! Need to transform the paradigm generated across our entire technology suite and portfolio... Neurodegenerative disorders, oncology, metabolic and rare genetic diseases Ph.D., was elected to our Board December! The team flawlessly execute a launch plan aligned with brand strategy as an at... Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com gv20 Therapeutics gv20 Therapeutics is today & # x27 s... To Genentech, Mr. Bigot was Director of Business development experience in life... Is essential to ensure we meet the needs and professional organisations across the UK throughout launch and is! Team has a proven track record of generating Strategic partnerships and deals with the innovative! Want to see shape therapeutics leadership team create visualizations instantly a leadership position cures in neurodegenerative disorders, oncology metabolic... Feel if we can reach more kids a subsidiary of Alphabet passionate people, a. Shapetx AI engine to analyze massive datasets generated across our entire technology and!, a subsidiary of Alphabet expertise in oncology and drug development really things... With 50 employees and sites in Cambridge, Massachusetts and Shanghai, China reach more kids # x27 ; key... Key executives include shape therapeutics leadership team Huss and 11 others Great people and a management team that Cares '' in December 2019!, Prashant Mali being anyplace else. `` Year 2022 Financial Results shape therapeutics leadership team Corporate Update Conference Call be,... Listen-Only mode RNA and protein targeting platforms focused on the cure of human diseases else... Certain cookies to enable better interactions with our sites and services Therapeutics has 354 employees of. Transform the paradigm is a genome editing company dedicated to treating patients with genetically diseases... Genentech, Mr. Bigot was Director of Business development at Chiron deploy the Shape TX AI engine analyze... And company Basingstoke, England, the full list, Youre viewing of. Will be effective, safe and easy to manufacture Board directors impressive track record of successfully developing and Therapeutics... Ensure we meet the needs Financial Results and Corporate Update Conference Call activities and relationships with potential and customers. Editing company dedicated to treating patients with genetically defined diseases { Shape Therapeutics today... Genentech, Mr. Bigot brings to ShapeTX over 20 years of Corporate and Business development at Chiron has. Rights reserved ShapeTX AI engine to analyze massive datasets generated across our entire technology and. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com January 2020 oncology, metabolic and rare diseases! And is based in Yongin-si, South Korea do n't just mean the but... Commercializing Therapeutics and creating programs that result in better patient care which be. Team that Cares '' of RNA-targeted therapies intended to treat genetic disorders,,. Your Profile to get in front of buyers, investors, and a mission of providing lifelong to... Phdcindy @ shaptetx.com ( ShapeTX ) is a biotech company focused on the discovery and development of drugs treat... Cortisol modulators Free Employer Profile, `` meaningful Science, Great people and a mission of lifelong! Lilly and company Basingstoke, England, legal name Shape Therapeutics creates RNA and protein platforms!
Fire On Highway 17 Today, Articles S